Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.
Sponsor Study ID: DSP-5336-101
Study Title: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation
CTO #: 103779
NCT Number: NCT04988555
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Myeloid and Monocytic Leukemia
Study Objectives: A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.